Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Long-term treatment of osteogenesis imperfects tarda in adults with salmon calcitonin and calcium

Journal Article · · Curr. Ther. Res., Clin. Exp.; (United States)
OSTI ID:7190359
Three postmenopausal women with osteogenesis imperfecta (O.I.) tarda were treated with daily salmon calcitonin (sCT) and calcium supplements for 12 to 33 months. Total body calcium (TBCa) measured by total body neutron activation analysis revealed a marked deficit exceeding that of severely osteoporotic women. In one patient a rapid loss of TBCa of 5 percent at five months of treatment was partially reversed after twelve months of treatment. In eight subsequent months of Ca supplementation alone, the loss of TBCa resumed and amounted to 11 percent. The second patient increased TBCa by 9 percent after a total of 33 months of sCT and Ca supplementation. The third patient also showed a rapid decrease in TBCa of 8 percent during one year of sCT and Ca, but she was also receiving systemic corticosteroids for asthma. Her TBCa recovered to 8 percent above baseline eight months after stopping sCT, continuation of the Ca and a drastic decrease in the dose of corticosteroids. The action of sCT in this patient might have been impaired by the concomitant administration of corticosteroids. Urinary hydroxyproline decreased from initial normal values in two patients suggesting continued inhibition of bone resorption. The results confirm previous work using calcitonin in children with O.I. and suggest that sCT may also be of benefit in adults with O.I. (auth)
Research Organization:
Brookhaven National Lab., Upton, NY
OSTI ID:
7190359
Journal Information:
Curr. Ther. Res., Clin. Exp.; (United States), Journal Name: Curr. Ther. Res., Clin. Exp.; (United States) Vol. 19:2; ISSN CTCEA
Country of Publication:
United States
Language:
English